Pharmacology of CCKRs and SAR studies of peptidic analog ligands

Current Topics in Medicinal Chemistry

Volumn 7, Issue 12, 2007, Pages 1173-1179

  Noble, Florence ^a,b,c  

^a CNRS   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

CCK2 Antagonists; antinociceptive effects; opioids; Structure affinity relationships; CCK2 receptor

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; [2 [(2 HYDROXYCYCLOHEXYL)AMINO] 1 (1H INDOL 3 YLMETHYL) 1 METHYL 2 OXOETHYL]CARBAMIC ACID 2 ADAMANTYL ESTER; A 70874; A 71378; BBL 454; BC 197; BC 254; CHOLECYSTOKININ; CHOLECYSTOKININ 4 RECEPTOR STIMULATING AGENT; CHOLECYSTOKININ 6 RECEPTOR STIMULATING AGENT; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR STIMULATING AGENT; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; HORMONE RECEPTOR STIMULATING AGENT; JMV 179; N TERT BUTYLOXYCARBONYLCHOLECYSTOKININ[27-32][28,31 NORLEUCINE] PHENETHYL ESTER; N TERT BUTYLOXYCARBONYLTRYPTOPHYL[NEPSILON (2 METHYLPHENYLAMINOCARBONYL)LYSYL]ASPARTYL N METHYLPHENYLALANINAMIDE; OPIATE; OPIATE RECEPTOR; RB 210; RB 360; RB 400; SNF 9007; UNCLASSIFIED DRUG;

ANTINOCICEPTION; BINDING AFFINITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; MOLECULAR DYNAMICS; NOCICEPTION; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; DRUG DESIGN; HUMANS; LIGANDS; PEPTIDES; RECEPTORS, CHOLECYSTOKININ; RECEPTORS, OPIOID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34447251038     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607780960447     Document Type: Review

References (60)

1. Rehfeld, J. H.; Nielsen, F. C. Molecular forms and regional distribution of cholecystokinin in the central nervous system; RG landes Company: Austin, 1995; pp. 33-56.
2. 1H NMR spectroscopy, fluorescence tranfer measurements and calculations. Biochem. 1986, 25, 3778-3787.
3. Charpentier, B.; Pélaprat, D.; Durieux, C.; Dor, A.; Reibaud, M. et al. Cyclic cholecystokinin analogues with high selectivity for central receptors. Proc. Natl. Acad. Sci. USA 1988, 85, 1968-1972.
4. 8 selective for central receptors. J. Med. Chem. 1989, 31, 1184-1190.
5. Migaud, M.; Durieux, C.; Viereck, J.; Soroca-Lucas, E.; Fournié-Zaluski, M. C. et al. The in vivo metabolism of cholecystokinin (CCK-8) is essentially ensured by aminopeptidase A. Peptides 1996, 17, 601-607.
6. Camus, A.; Rose, C.; Schwartz, J. C. Role of a serine endopeptidase in the hydrolysis of exogenous cholecystokinin by brain slices. Neuroscience 1989, 29, 595-602.
7. Rose, C.; Vargas, F.; Facchinetti, P.; Bourgeat, P.; Bambal, R. B. et al. Characterization and inhibition of a cholecystokinin-inactivating serine peptidase. Nature (Lond.) 1996, 380, 403-409.
8. Ruiz-Gayo, M.; Daugé, V.; Menant, I.; Bégué, D.; Gacel, G. et al. Synthesis and biological activity of Boc(Nle28, Nle31)CCK27-33 a highly potent CCK8 analogue. Peptides 1985, 6, 415-420.
9. Durieux, C.; Charpentier, B.; Pelaprat, D.; Roques, B. P. Investigation on the metabolism of CCK8 analogues by rat brain slices. Neuropeptides 1986, 7, 1-9.
10. Charpentier, B.; Durieux, C.; Pélaprat, D.; Dor, A.; Reibaud, M. et al. Enzyme-resistant CCK analogs with high affinities for central receptors. Peptides 1988, 9, 835-841.
11. 3H]pBC 264. Eur. J. Pharmacol. 1991, 209, 185-193.
12. Durieux, C.; Corringer; P. J.; Bergeron, F.; Roques, B. P. [3H]pBC 264, first highly potent and very selective radioligand for CCK-B receptors. Eur. J. Pharmacol. 1989, 168, 269-270.
13. De Montigny, C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch. Gen. Psychiatry 1989, 46, 511-517.
14. Bradwejn, J.; Koszycki, D.; Shriqui, C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Arch. Gen. Psychiatry 1991, 48, 603-610.
15. Harhammer, R.; Schafer, U.; Henklein, P.; Ott, T.; Repke, H. CCK-8-related C-terminal tetrapeptides: affinities for central CCKB and peripheral CCKA receptors. Eur. J. Pharmacol. 1991, 209, 263-266.
16. 4 derivatives. J. Med. Chem. 1993, 36, 166-172.
17. 2. Biopolymers 1994, 34, 155-159.
18. Nadzan, A. M.; Garvey, D. S.; Holladay, M. W.; Shiosaki, K.; Tufano, M. D. et al. Design of cholecystokinin analogs with high affinity and selectivity for brain receptors; ESCOM: Leiden, 1991; 101-102.
19. 4; ESCOM: Leiden, 1990; 978-980.
20. 4 analogs: synthesis, and implication for the CCK-B receptor-bound conformation. J. Med. Chem. 1995, 38, 137-149.
21. Weng, J. H.; Bado, A.; Garbay, C.; Roques, B. P. Novel CCK-B receptor agonists: diketopiperazine analogues derived for CCK4 bioactive conformation. Regul. Pept. 1996, 65, 3-9.
22. Blommaert, A. G.; Dhotel, H.; Ducos, B.; Durieux, C.; Goudreau, N. et al. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor. J. Med. Chem. 1997, 40, 647-658.
23. De Luca, S.; Saviano, M.; Della Moglie, R.; Digilio, G.; Bracco, C. et al. Conformationally Constrained CCK8 Analogues Obtained from a Rationally Designed Peptide Library as Ligands for Cholecystokinin Type B Receptor. ChemMedChem 2006, 1, 997-1006.
24. Weng, J. H.; Blommaert, A. G.; Moizo, L.; Bado, A.; Ducos, B. et al. Role of N- and C-terminal substituents on the CCK-B agonist-antagonist pharmacological profile of Boc-Trp-Phg-Asp-Na1-NH2 derivatives. Bioorg. Med. Chem. 1996, 4, 563-573.
25. Million, M. E.; Léna, I.; Da Nascimento, S.; Noble, F.; Daugé, V. et al. Development of new potent agonists able to interact with two postulated subsites of the cholecystokinin CCK-B receptor. Lett. Pept. Sci. 1997, 4, 407-410.
26. Bellier, B.; Crete, D.; Million, M. E.; Beslot, F.; Bado, A. et al. New CCK2 agonists confirming the heterogeneity of CCK2 receptors: characterisation of BBL454. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 370, 404-413.
27. Bock M. G.; DiPardo, R. M.; Evans, B. E.; Rittle, K. E.; Whitter, W. L. et al. Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260. J. Med Chem. 1989, 32 13-16.
28. Horwell, D. C.; Hughes, J.; Hunter, J. C.; Pritchard, M. C.; Richardson, R. S. et al. Rationally designed "dipeptoid" analogues of CCK. alpha-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties. J. Med. Chem. 1991, 34, 404-414.
29. Bohme, G. A.; Bertrand, P.; Guyon, C.; Capet, M.; Pendley, C. et al. The ureidoacetamides, a novel family of non-peptide CCK-B/gastrin antagonists. Ann. N Y Acad. Sci. 1994, 713, 118-120.
30. Rasmussen, K.; Czachura, J. F.; Stockton, M. E.; Howbert, J. J. Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons. J. Pharmacol. Exp. Ther. 1993, 264, 480-488.
31. Yu, M. J.; Thrasher, K. J.; McCowan, J. R.; Mason, N. R.; Mendelsohn, L. G. Quinazolinone cholecystokinin-B receptor ligands. J. Med. Chem. 1991, 34, 1505-1508.
32. Dethloff, L. A.; de la Iglesia, F. A. Cholecystokinin antagonists-a toxicologic perspective. Drug Metab. Rev. 1992, 24, 267-293.
33. Chen, I. W.; Dorley, J. M.; Ramjit, H. G.; Pitzenberger, S. M.; Lin, J. H. Physiological disposition and metabolism of L-365,260, a potent antagonist of brain cholecystokinin receptor, in laboratory animals. Drug Metab. Dispos. 1992, 20, 390-395.
34. Gonzalez-Muniz, R.; Bergeron, F.; Marseigne, I.; Durieux, C.; Roques, B. P. Boc-Trp-Orn(Z)-Asp-NH2 and derivatives: a new family of CCK antagonists. J. Med. Chem. 1990, 33, 3199-3204.
35. Blommaert, A. G.; Weng, J. H.; Dorville, A.; McCort, I.; Ducos, B. et al. Cholecystokinin peptidomimetics as selective CCK-B antagonists: design, synthesis, and in vitro and in vivo biochemical properties. J. Med Chem. 1993, 36, 2868-2877.
36. Hocker, M.; Hughes, J.; Folsch, U. R.; Schmidt; W. E. PD 135158, a CCKB/ gastrin receptor antagonist, stimulates rat pancreatic enzyme secretion as a CCKA receptor agonist. Eur. J. Pharmacol. 1993, 242, 105-108.
37. Ding, X. Q.; Chen, D.; Hakanson, R. Cholecystokinin-B receptor ligands of the dipeptoid series act as agonists on rat stomach histidine decarboxylase. Gastroenterology 1995, 109, 1181-1187.
38. Fincham, C. I.; Horwell, D. C.; Ratcliffe, G. S.; Rees, D. C. The use of a proline ring as a conformational restraint in CCK-B receptor "dipeptoids". BioMed. Chem. Lett. 1992, 2, 403-406.
39. Fincham, C. I.; Higginbottom, M.; Hill, D. R.; Horwell, D. C.; O'Toole, J. C. et al. Amide bond replacements incorporated into CCK-B selective "dipeptoids". J. Med. Chem. 1992, 35, 1472-1484.
40. Didier, E.; Horwell, D. C.; Pritchard, M. C. Synthesis and CCK-B binding affinities of cyclic analogues of the potent and selective CCK-B antagonist, CI-988. Tetrahedron 1992, 48, 8471-8490.
41. Bolton, G. L.; Roth, B. D.; Trivedi, B. K. Synthesis of conformationally constrained macrocyclic analogues of the potent and selective CCK-B antagonist CI-988. Tetrahedron 1993, 49, 525-536.
42. Higginbottom, M.; Hill, D. R.; Horwell, D. C.; Mostafai, E.; Suman-Chauhan, N. et al. Conformationally restricted analogues of the potent CCK-B antagonist CI-988. Bioorg. Med. Chem. 1993, 1, 209-217.
43. Bellier, B.; McCort-Tranchepain, I.; Ducos, B.; Danascimento, S.; Meudal, H. et al. Synthesis and biological properties of new constrained CCK-B antagonists: discrimination of two affinity states of the CCK-B receptor on transfected CHO cells. J. Med. Chem. 1997, 40, 3947-3956.
44. Bellier, B.; Da Nascimento, S.; Meudal, H.; Gincel, E.; Roques, B. P. et al. Novel constrained CCK-B dipeptoid antagonists derived from pipecolic acid. Bioorg. Med. Chem. Lett. 1998, 8, 1419-1424.
45. Trivedi, B. K.; Padia, J. K.; Holmes, A.; Rose, S.; Wright, D. S. et al. Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. J. Med. Chem. 1998, 41, 38-45.
46. Holladay, M. W.; Bennett, M. J.; Tufano, M. D.; Lin, C. W.; Asin, K. E. et al. Synthesis and biological activity of CCK heptapeptide analogues. Effects of conformational constraints and standard modifications on receptor subtype selectivity, functional activity in vitro, and appetite suppression in vivo. J. Med. Chem. 1992, 35, 2919-2928.
47. Galas, M. C.; Lignon, M. F.; Rodriguez, M.; Mendre, C.; Fulcrand, P. et al. Structure-activity relationship studies on cholecystokinin: analogues with partial agonist activity. Am. J. Physiol. 1988, 254, G176-182.
48. Pierson, M. E.; Comstock, J. M.; Simmons, R. D.; Kaiser, F.; Julien, R. et al. Synthesis and biological evaluation of potent, selective, hexapeptide CCK-A agonist anorectic agents. J. Med. Chem. 1997, 40, 4302-4307.
49. Lignon, M. F.; Galas, M. C.; Rodriguez, M.; Laur, J.; Aumelas, A. et al. A synthetic peptide derivative that is a cholecystokinin receptor antagonist. J. Biol. Chem. 1987, 262, 7226-7231.
50. Sugg, E. E.; Kimery, M. J.; Ding, J. M.; Kenakin, D. C.; Miller, L. J. et al. CCK-A receptor selective antagonists derived from the CCK-A receptor selective tetrapeptide agonist Boc-Trp-Lys(Tac)-Asp-MePhe-NH2 (A-71623). J. Med. Chem. 1995, 38, 207-211.
51. Gall, C.; Lauterborn, J.; Burks, D.; Seroogy, K. Co-localization of enkephalins and cholecystokinin in discrete areas of rat brain. Brain Res. 1907, 403, 403-408.
52. 5-enkephalin-, and dynorphin A (1-8)-like materials in the spinal cord and dorsal root ganglia of adult rats: effetcs of dorsal rhizotomy and neonatal capsaicin. J. Neurochem. 1990, 55, 1122-1130.
53. Faris, P. L.; Komisaruk, B. R.; Watkins, L. R.; Mayer, D. J. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 1983, 219, 310-312.
54. Faris, P. L.; McLaughlin, C. L.; Baile, C. A.; Olney, J. W.; Komisaruk, B. R. Morphine analgesia potentiated but tolerance not affected by active immunization against cholecystokinin. Science 1984, 226, 1215-1217.
55. Baber, N. S.; Dourish, C. T.; Hill, D. R. The role of CCK, caerulein, and CCK antagonists in nociception. Pain 1999, 39, 307-328.
56. Boteju, L. W.; Nikiforovich, G. V.; Haskell-Luevano, C.; Fang, S. N.; Zalewska, T. et al. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors. J. Med. Chem. 1996, 39, 4120-4124.
57. Hruby, V. J.; Porreca, F.; Yamamura, H. I.; Tollin, G.; Agnes, R. S. et al. New paradigms and tools in drug design for pain and addiction. AAPS J. 2006, 8, E450-460.
58. Ivy, A. C.; Oldberg, E. A hormone mechanism for gallbladder contraction and evacuation. Am. J. Physiol. 1928, 86, 599-613.
59. Jorpes, J. E.; Mutt, V. Cholecystokinin and pancreozymin, one single hormone? Acta Physiol. Scand. 1966, 66, 196.
60. Vanderhaeghen, J. J.; Signeau, J. C.; Gepts, W. New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature (Lond.) 1975, 257, 604-605.